Welcome to our dedicated page for Collplant Biotechnologies news (Ticker: CLGN), a resource for investors and traders seeking the latest updates and insights on Collplant Biotechnologies stock.
CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) pioneers regenerative medicine solutions through its plant-based recombinant human collagen (rhCollagen) technology. This dedicated news hub provides investors and stakeholders with timely updates on clinical advancements, strategic partnerships, and product developments in 3D bioprinting, medical aesthetics, and tissue repair.
Access official press releases covering regulatory milestones, research breakthroughs, and commercial collaborations with industry leaders like AbbVie and Stratasys. Our curated collection includes updates on Vergenix™ wound care products, rhCollagen BioInk applications, and progress in regenerative breast implant development.
Discover comprehensive coverage of financial results, intellectual property expansions, and manufacturing scale-up initiatives. This resource serves as your primary source for tracking CollPlant's progress in addressing unmet needs across orthobiologics, advanced wound care, and organ manufacturing markets.
Bookmark this page for streamlined access to CLGN's latest developments in biocompatible medical solutions. Check regularly for updates on ESG initiatives, patent filings, and clinical trial outcomes that shape the company's position in the $3B+ regenerative medicine sector.
CollPlant Biotechnologies (Nasdaq: CLGN) announced its participation in the International Conference on Biofabrication 2025, scheduled for September 14-17, 2025, in Warsaw, Poland. The company will deliver two presentations: "rhCollagen Bioinks for Biofabrication" on September 16th during the Industrial Session, and "Mechanical Computational Modeling and Simulation of Biodegradable Implants" on September 17th.
The company will showcase its rhCollagen platform and biofabrication applications at an exhibition booth. CollPlant's rhCollagen-based bioinks are designed for 3D bioprinting applications in medical research, featuring controlled rheology, non-animal safety profile, biocompatibility, and tunable mechanical properties.
CollPlant Biotechnologies (NASDAQ: CLGN), a company focused on regenerative and aesthetics medicine using non-animal-derived recombinant human collagen technology, has announced its participation in the 27th Annual H.C. Wainwright Global Investment Conference.
The conference will take place on September 8-9, 2025, at the Lotte New York Palace Hotel. Senior management will be available for one-on-one meetings with investors, which can be arranged through H.C. Wainwright representatives or via meetings@hcwco.com.
CollPlant Biotechnologies (NASDAQ:CLGN) reported Q2 2025 financial results and provided updates on its key programs. The company recorded revenues of $179,000 in Q2 2025, down from $249,000 in Q2 2024, with a net loss of $3.3 million. For the first half of 2025, revenues reached $2.2 million, primarily due to a $2 million milestone payment from AbbVie.
Key developments include advancing its photocurable dermal filler program toward clinical stage, progress in regenerative breast implants development with successful 3D bioprinting of 200cc commercial-size implants, and expansion of Vergenix™ STR distribution into new markets. The company strengthened its financial position through a $3.6 million registered direct offering and ended Q2 with $11.4 million in cash.
CollPlant also appointed Bowman Bagley as VP of Commercial North America and expanded its agreement with STEMCELL Technologies for broader use of its rhCollagen technology.
CollPlant Biotechnologies (NASDAQ: CLGN), a company specializing in regenerative and aesthetics medicine, has scheduled its second quarter 2025 financial results announcement for Wednesday, August 20, 2025, before U.S. markets open. The company, known for its innovative non-animal-derived rhCollagen technology for tissue regeneration and medical aesthetics, will provide updates on its financial performance.
CollPlant Biotechnologies (NASDAQ:CLGN) has appointed Bowman Bagley as Vice President, Commercial North America in a newly created position. Bagley, who previously served as VP at Wasatch Biolabs and CEO at Advanced BioMatrix, will lead the company's commercial strategy and execution in North America.
The appointment aligns with CollPlant's growth strategy for its non-animal-derived recombinant human collagen (rhCollagen) technology. Bagley will oversee sales, marketing, logistics, and market expansion for CollPlant's rhCollagen-based products and platforms, particularly focusing on bioinks portfolio growth and research market sales.
Bagley brings extensive experience in collagen-based biomaterials, 3D bioprinting, and tissue engineering, along with a track record in sales, product development, and licensing. He holds a B.S. in Neuroscience and an MBA from the University of Utah.
CollPlant Biotechnologies (NASDAQ: CLGN), a company specializing in regenerative and aesthetics medicine with a focus on non-animal-derived rhCollagen technology, has announced it will release its first quarter 2025 financial results on Wednesday, May 28, 2025, before U.S. markets open. The company develops innovative technologies and products for tissue regeneration and medical aesthetics applications.